Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
34,100
Employees34,100
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
34,100
Employees34,100

BMY Key Statistics

Market cap
111.44B
Market cap111.44B
Price-Earnings ratio
18.46
Price-Earnings ratio18.46
Dividend yield
4.54%
Dividend yield4.54%
Average volume
19.53M
Average volume19.53M
High today
$54.78
High today$54.78
Low today
$54.01
Low today$54.01
Open price
$54.68
Open price$54.68
Volume
16.58M
Volume16.58M
52 Week high
$63.33
52 Week high$63.33
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

The current Bristol-Myers Squibb(BMY) stock price is $54.38, with a market capitalization of 111.44B. The stock trades at a price-to-earnings (P/E) ratio of 18.46 and offers a dividend yield of 4.5%.

During the trading session on 2025-12-24, Bristol-Myers Squibb(BMY) shares reached a daily high of $54.78 and a low of $54.01. At a current price of $54.38, the stock is +0.7% higher than the low and still -0.7% under the high.

Trading activity shows a volume of 16.58M, compared to an average daily volume of 19.53M.

Over the past 52 weeks, Bristol-Myers Squibb(BMY) stock has traded between a high of $63.33 and a low of $42.52.

Over the past 52 weeks, Bristol-Myers Squibb(BMY) stock has traded between a high of $63.33 and a low of $42.52.

BMY News

TipRanks 2d
Bristol-Myers Squibb: Stable Cash Flows Offset by Slower Cobenfy Ramp Support Hold Rating

Evan Seigerman, an analyst from BMO Capital, maintained the Hold rating on Bristol-Myers Squibb. The associated price target remains the same with $47.00. Claim...

TipRanks 5d
New Pumitamig Kidney Cancer Trial Adds Long-Term Optionality for Bristol-Myers Squibb and BioNTech

Biontech Se Sponsored Adr (BNTX), Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and In...

Simply Wall St 6d
What Bristol-Myers Squibb's Oncology Milestones and Steady Dividend Mean For Shareholders

Bristol Myers Squibb recently reported a series of oncology milestones, including FDA priority review for Opdivo plus AVD in advanced classical Hodgkin lymphoma...

What Bristol-Myers Squibb's Oncology Milestones and Steady Dividend Mean For Shareholders

Analyst ratings

62%

of 29 ratings
Buy
34.5%
Hold
62.1%
Sell
3.4%

More BMY News

TipRanks 7d
Bristol-Myers Squibb to Launch Phase 3 Trial for Schizophrenia Drug KarXT in Adolescents

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge...

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.